Research Analysts Offer Predictions for BNGO Q3 Earnings

Bionano Genomics, Inc. (NASDAQ:BNGO) – Analysts at Maxim Group issued their Q3 2026 earnings estimates for shares of Bionano Genomics in a research report issued to clients and investors on Friday, November 6th. Maxim Group analyst M. Okunewitch anticipates that the company will post earnings of ($0.45) per share for the quarter. The consensus estimate for Bionano Genomics’ current full-year earnings is ($2.49) per share.

A number of other research analysts have also recently commented on BNGO. Weiss Ratings upgraded Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. Wall Street Zen raised Bionano Genomics to a “hold” rating in a research note on Saturday, September 26th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

Bionano Genomics Price Performance

Shares of BNGO opened at $1.16 on Tuesday. Bionano Genomics has a 1-year low of $1.00 and a 1-year high of $2.23. The stock has a market cap of $16.22 million, a PE ratio of -0.38 and a beta of 1.73. The firm has a 50-day simple moving average of $1.37 and a two-hundred day simple moving average of $1.23. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.96.

Bionano Genomics (NASDAQ:BNGO) last posted its earnings results on Monday, August 10th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 78.78%. The company had revenue of ($6.67) million for the quarter, compared to analysts’ expectations of $7.55 million.

Institutional Investors Weigh In On Bionano Genomics

Institutional investors have recently modified their holdings of the company. Carret Asset Management LLC grew its position in Bionano Genomics by 8.4% during the 3rd quarter. Carret Asset Management LLC now owns 135,545 shares of the company’s stock worth $211,000 after purchasing an additional 10,545 shares during the last quarter. Renaissance Technologies LLC increased its stake in Bionano Genomics by 31.6% in the first quarter. Renaissance Technologies LLC now owns 48,700 shares of the company’s stock valued at $57,000 after purchasing an additional 11,700 shares during the period. GSA Capital Partners LLP acquired a new position in Bionano Genomics in the second quarter valued at $170,000. Finally, AIGH Capital Management LLC purchased a new stake in shares of Bionano Genomics in the third quarter valued at about $1,817,000. 11.35% of the stock is owned by hedge funds and other institutional investors.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations.

The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.